Non-V delta 2 gamma delta T lymphocytes as effectors of cancer immunotherapy
暂无分享,去创建一个
[1] Nigel Klein,et al. Neuroblastoma Killing Properties of Vδ2 and Vδ2-Negative γδT Cells Following Expansion by Artificial Antigen-Presenting Cells , 2014, Clinical Cancer Research.
[2] R. Bast,et al. Activating and Propagating Polyclonal Gamma Delta T Cells with Broad Specificity for Malignancies , 2014, Clinical Cancer Research.
[3] K. Gustafsson,et al. γδ T cells for cancer immunotherapy , 2014, Oncoimmunology.
[4] Antoni Ribas,et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.
[5] L. Hurton,et al. Bispecific T-cells expressing polyclonal repertoire of endogenous γδ T-cell receptors and introduced CD19-specific chimeric antigen receptor. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.
[6] G. Laurent,et al. What lessons can be learned from γδ T cell-based cancer immunotherapy trials? , 2012, Cellular and Molecular Immunology.
[7] L. Saraiva,et al. Human γδ T Lymphocytes Are Licensed for Professional Antigen Presentation by Interaction with Opsonized Target Cells , 2012, The Journal of Immunology.
[8] B. Moser,et al. Professional Antigen-Presentation Function by Human γδ T Cells , 2005, Science.
[9] A. Lim,et al. High frequency of circulating γδ T cells with dominance of the Vδ1 subset in a healthy population , 2000 .
[10] O. Janssen,et al. Activation and Activation‐Driven Death of Human γδ T Cells , 1991, Immunological reviews.
[11] B. Moser,et al. Professional antigen-presentation function by human gammadelta T Cells. , 2005, Science.
[12] A. Lim,et al. High frequency of circulating gamma delta T cells with dominance of the v(delta)1 subset in a healthy population. , 2000, International immunology.